- Details
- Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...
|
- Details
- Kara Watts from Montefiore Medical Center and Jen Robles from Vanderbilt University Medical Center shared insights from the AUA's 2023 Quality Improvement Summit, which focused on integrating telehealth into urology. They discussed the importance of telehealth in providing safe, effective, and satisfactory care, especially for patients with sensitive needs or disabilities. Despite the decrease in...
|
- Details
- Guillaume Grisay introduces the De-Escalate trial, a study focused on intermittent treatment for metastatic hormone-naive prostate cancer patients who have achieved a deep PSA response after induction therapy. This innovative approach aims to preserve overall survival while improving patients' quality of life by pausing ADT and AR pathway inhibitors, addressing the challenges of chronic toxicities...
|
- Details
- Neal Shore discusses the ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment strateg...
|
- Details
- Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...
|
- Details
- Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. The conversation with Dr. Sam Chang reveals no safety concerns with the combination of TKI and immuno...
|
- Details
- Tanya Stoyanova discusses research on Trop2's role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study reveals Trop2 as a high-potential therapeutic target due to its overexpression in various epithelial cancers, including prostate cancer, where it's linked to aggressive behavior. Their work, validated in a large patient cohort...
|
- Details
- Historically, conventional imaging techniques have been used for the assessment of clinical progression in biochemical recurrence (BCR). However, these imaging technologies have limited sensitivity at low PSA values (<10 ng/mL). Next-generation imaging (NGI) technologies may overcome the sensitivity limitations associated with low PSA values and offer improved diagnostic accuracy for identifying B...
|
- Details
- Judd Moul discusses a study focusing on the mortality risk associated with androgen deprivation therapy (ADT) in Black versus white patients with prostate cancer. The study, a comprehensive analysis of a large cohort, indicates that African-American ethnicity may be protective for survival in both castrate-resistant and castrate-sensitive prostate cancer. This contradicts earlier perceptions, espe...
|
- Details
- Alicia Morgans, Mark Markowski, and Emmanuel Antonarakis discuss research on high-dose testosterone therapy for metastatic castration-resistant prostate cancer, inspired by Sam Denmeade's paradoxical approach. The COMBAT trial, a phase II study, explored the efficacy of combining bipolar androgen therapy (BAT) with the immune checkpoint inhibitor nivolumab, revealing notable PSA response rates and...
|
